Related Experiment Video

Updated: May 6, 2026

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

8.7K

Advanced Cardiac Patches for the Treatment of Myocardial Infarction

Tailuo Liu1,2,3, Ying Hao1, Zixuan Zhang4

  • 1Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases (T.L., Y.H., H.Z., S.P., D.Z., Y.C., M.C.), West China Hospital, Sichuan University, Chengdu, PR China.

Circulation
|June 17, 2024
PubMed

Insights

Cardiac patches offer a promising solution for myocardial infarction (MI), a leading cause of heart failure. This review explores patch materials and fabrication for improved cardiac restoration.

Area of Science:

  • Cardiovascular Medicine
  • Biomaterials Science
  • Regenerative Medicine

Background:

  • Myocardial infarction (MI) leads to heart failure through ischemia/reperfusion injury, inflammation, fibrosis, and ventricular remodeling.
  • Current therapies improve short-term survival but have limited long-term efficacy in restoring cardiac function.
  • Cardiac patches are emerging as a promising therapeutic strategy for myocardial infarction.

Purpose of the Study:

  • To review the pathophysiological progression of myocardial infarction to heart failure.
  • To highlight therapeutic targets and various cardiac patch strategies for cardiac restoration.
  • To discuss scaffold materials, fabrication techniques, properties, and delivery strategies for cardiac patches.

Main Methods:

  • Literature review of pathophysiological mechanisms of myocardial infarction and heart failure.
  • Analysis of current and emerging cardiac patch technologies.
  • Evaluation of scaffold materials (synthetic, natural, conductive) and fabrication methods.
  • Assessment of advanced delivery strategies and optimal patch properties.

Main Results:

  • Cardiac patches provide mechanical reinforcement, electrical conduction, and localized therapeutic delivery.
  • Scaffold materials, fabrication techniques, and delivery strategies significantly influence patch efficacy.
  • Various approaches are being explored to promote cardiac restoration post-myocardial infarction.

Conclusions:

  • Cardiac patches represent a significant advancement in treating myocardial infarction and preventing heart failure.
  • Further research into limitations and prospects is crucial for clinical translation of innovative cardiac patch products.
  • Optimized cardiac patches hold potential for long-lasting improvements in cardiac function and patient outcomes.

Keywords:
biocompatible materialsmyocardial infarctionstem cellstissue engineering

More Related Videos

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model07:03

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

7.2K
Transplantation of a 3D Bioprinted Patch in a Murine Model of Myocardial Infarction07:47

Transplantation of a 3D Bioprinted Patch in a Murine Model of Myocardial Infarction

Published on: September 26, 2020

6.6K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
346
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
528
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.7K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
802
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
762